ClearPoint Neuro Guides Up to $60M 2026 Revenue After 20% Q4 Growth

Edgen Stock·Jan 13 2026, 01:50

Share to

Share to

Copy link

Key Takeaways

ClearPoint Neuro announced strong preliminary financial results for the fourth quarter and full year of 2025, signaling robust growth momentum. The company's performance was driven by significant gains in its core business segments, leading to a confident and optimistic revenue forecast for 2026.

Q4 2025 Revenue: Preliminary revenue for the fourth quarter reached approximately $10.4 million, marking a 20% increase in comparable sales versus the prior year.
Strong 2026 Guidance: The company projects total revenues for 2026 to be between $54 million and $60 million, supported by organic growth and recent acquisitions.
Segment Strength: Growth was powered by a 23% increase in functional neurosurgery disposables and a 26% increase in biologics and drug delivery.

Q4 Revenue Climbs 20% to $10.4 Million

ClearPoint Neuro (Nasdaq:CLPT) announced on January 12, 2026, that its preliminary unaudited revenue for the fourth quarter of 2025 reached approximately $10.4 million. This figure represents a 20% increase in comparable sales compared to the fourth quarter of 2024. The reported growth does not include sales from the IRRA_flow product line, which was acquired late in the quarter. For the full year 2025, the company reported preliminary unaudited revenue of approximately $37 million, capping a strong year.

Company Projects 2026 Revenue to Reach Up to $60 Million

Looking ahead, ClearPoint Neuro issued an optimistic forecast for 2026, projecting total revenues to fall between $54 million and $60 million. Management attributes this outlook to a combination of organic growth and the successful integration of the IRRA_flow product line. According to CEO Joe Burnett, the strong Q4 results provide "excellent momentum" for 2026. The company expects double-digit growth across all four of its key markets: biologics and drug delivery, neurosurgery navigation, laser therapy, and intracranial fluid management.

Biologics and Neurosurgery Segments Post Over 23% Gains

The fourth quarter's performance was propelled by strong results in the company's high-growth divisions. Revenue from functional neurosurgery disposables increased by 23%, while the biologics and drug delivery segment grew by 26%. This performance underscores the increasing adoption of ClearPoint's enabling technologies for brain and spine navigation. The company stated its strategy is to continue growing its installed base, which will fund the infrastructure needed to support the future commercial launch of neuro cell and gene therapies.